Nasdaq
$2.98▲ 0.34%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $101.4MShares out 34.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 2d agoAfter-hours26.10.23 06:444Ownership#●●●
Anixa Biosciences Inc
Insider Kumar Amit of Anixa Biosciences Inc reported a change in beneficial ownership of securities on October 22, 2026. This filing is a Form 4 statement detailing the insider's updated equity holdings.…more
$2.98+0.34%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30Regular26.09.30 23:254Ownership
Anixa Biosciences Inc
Anixa Biosciences insider Michael Catelani has filed a Form 4 to report changes in his beneficial ownership of company securities. This filing serves as a standard disclosure of equity transactions by corporate insiders.…more
$2.98+0.34%vs prev closeView filingShare - 9.28Pre-market26.09.28 21:454Ownership
Anixa Biosciences Inc
Insider Kumar Amit of Anixa Biosciences filed a Form 4 on September 28, 2026, reporting a change in beneficial ownership of securities as of September 24, 2026. This filing serves as a standard disclosure of equity transactions by company insiders.…more
$2.98+0.34%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:18#●●●#●●●
Anixa Biosciences Reports Stable Disease in Phase 1 Ovarian Cancer CAR-T Trial…more
Anixa Biosciences announced that a patient in its Phase 1 ovarian cancer CAR-T trial achieved stable disease 90 days after receiving the fifth dose cohort. No dose-limiting toxicities have been reported to date as the study continues to evaluate the therapy.…more
$2.98+0.34%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.1Pre-market26.10.01 21:40
●●●●●●●● ●●●●● ●●●●●●
Anixa Biosciences is advancing its Phase 1 clinical trial for an FSHR-targeted CAR-T therapy, with the fifth cohort currently receiving treatment. The company reported encouraging survival data in heavily pre-treated patients while maintaining a positive safety profile.…more
$2.98+0.34%vs prev closeShareBenzinga - 9.21Pre-market26.09.21 21:47
●●●●●●●● ●●●●● ●●●●●●
Anixa Biosciences has been granted an Australian patent for its breast cancer vaccine technology, which is exclusively licensed from the Cleveland Clinic. This patent provides protection through 2040 and expands the company's global intellectual property footprint.…more
$2.98+0.34%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report